Literature DB >> 18655141

Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides.

Yaniv Linde1, Oded Ovadia, Eli Safrai, Zhimin Xiang, Federico P Portillo, Deborah E Shalev, Carrie Haskell-Luevano, Amnon Hoffman, Chaim Gilon.   

Abstract

Backbone cyclization (BC) and N-methylation have been shown to enhance the activity and/or selectivity of biologically active peptides and improve metabolic stability and intestinal permeability. In this study, we describe the synthesis, structure-activity relationship (SAR) and intestinal metabolic stability of a backbone cyclic peptide library, BL3020, based on the linear alpha-Melanocyte stimulating hormone analog Phe-D-Phe-Arg-Trp-Gly. The drug lead, BL3020-1, selected from the BL3020 library (compound 1) has been shown to inhibit weight gain in mice following oral administration. Another member of the BL3020 library, BL3020-17, showed improved biological activity towards the mMC4R, in comparison to BL3020-1, although neither were selective for MC4R or MC5R. N-methylation, which restrains conformational freedom while increasing metabolic stability beyond that which is imparted by BC, was used to find analogs with increased selectivity. N-methylated backbone cyclic libraries were synthesized based on the BL3020 library. SAR studies showed that all the N-methylated backbone cyclic peptides demonstrated reduced biological activity and selectivity for all the analyzed receptors. N-methylation of active backbone cyclic peptides destabilized the active conformation or stabilized an inactive conformation, rendering the peptides biologically inactive. N-methylation of backbone cyclic peptides maintained stability to degradation by intestinal enzymes. (c) 2008 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18655141      PMCID: PMC2756785          DOI: 10.1002/bip.21057

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  49 in total

1.  Targeted disruption of the melanocortin-4 receptor results in obesity in mice.

Authors:  D Huszar; C A Lynch; V Fairchild-Huntress; J H Dunmore; Q Fang; L R Berkemeier; W Gu; R A Kesterson; B A Boston; R D Cone; F J Smith; L A Campfield; P Burn; F Lee
Journal:  Cell       Date:  1997-01-10       Impact factor: 41.582

2.  Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P.

Authors:  G Byk; D Halle; I Zeltser; G Bitan; Z Selinger; C Gilon
Journal:  J Med Chem       Date:  1996-08-02       Impact factor: 7.446

Review 3.  The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation.

Authors:  R D Cone; D Lu; S Koppula; D I Vage; H Klungland; B Boston; W Chen; D N Orth; C Pouton; R A Kesterson
Journal:  Recent Prog Horm Res       Date:  1996

4.  Role of melanocortinergic neurons in feeding and the agouti obesity syndrome.

Authors:  W Fan; B A Boston; R A Kesterson; V J Hruby; R D Cone
Journal:  Nature       Date:  1997-01-09       Impact factor: 49.962

5.  Molecular cloning, expression, and characterization of a fifth melanocortin receptor.

Authors:  I Gantz; Y Shimoto; Y Konda; H Miwa; C J Dickinson; T Yamada
Journal:  Biochem Biophys Res Commun       Date:  1994-05-16       Impact factor: 3.575

6.  Structure-activity relationships of dermorphin analogues containing N-substituted amino acids in the 2-position of the peptide sequence.

Authors:  R Schmidt; A Kálmán; N N Chung; C Lemieux; C Horváth; P W Schiller
Journal:  Int J Pept Protein Res       Date:  1995-07

7.  Molecular cloning of a novel melanocortin receptor.

Authors:  I Gantz; Y Konda; T Tashiro; Y Shimoto; H Miwa; G Munzert; S J Watson; J DelValle; T Yamada
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

8.  The cloning of a family of genes that encode the melanocortin receptors.

Authors:  K G Mountjoy; L S Robbins; M T Mortrud; R D Cone
Journal:  Science       Date:  1992-08-28       Impact factor: 47.728

9.  Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation.

Authors:  F E Ali; D B Bennett; R R Calvo; J D Elliott; S M Hwang; T W Ku; M A Lago; A J Nichols; T T Romoff; D H Shah
Journal:  J Med Chem       Date:  1994-03-18       Impact factor: 7.446

10.  Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA.

Authors:  V Chhajlani; J E Wikberg
Journal:  FEBS Lett       Date:  1992-09-14       Impact factor: 4.124

View more
  13 in total

Review 1.  Strategic approaches to optimizing peptide ADME properties.

Authors:  Li Di
Journal:  AAPS J       Date:  2014-11-04       Impact factor: 4.009

Review 2.  Novel approaches to the design of bioavailable melanotropins.

Authors:  Yang Zhou; Minying Cai
Journal:  Expert Opin Drug Discov       Date:  2017-07-12       Impact factor: 6.098

Review 3.  The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options.

Authors:  L Fani; S Bak; P Delhanty; E F C van Rossum; E L T van den Akker
Journal:  Int J Obes (Lond)       Date:  2013-06-18       Impact factor: 5.095

Review 4.  Conversion of Protein Active Regions into Peptidomimetic Therapeutic Leads Using Backbone Cyclization and Cycloscan - How to Do it Yourself!

Authors:  Samuel J S Rubin; Yftah Tal-Gan; Chaim Gilon; Nir Qvit
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

Review 5.  Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints.

Authors:  Jonathan E Bock; Jason Gavenonis; Joshua A Kritzer
Journal:  ACS Chem Biol       Date:  2012-11-30       Impact factor: 5.100

6.  Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists.

Authors:  Fa Liu; Andrew G Stephen; Abdul A Waheed; Eric O Freed; Robert J Fisher; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2009-10-29       Impact factor: 2.823

7.  New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties.

Authors:  Hongchang Qu; Daniel Ricklin; Hongjun Bai; Hui Chen; Edimara S Reis; Mateusz Maciejewski; Apostolia Tzekou; Robert A DeAngelis; Ranillo R G Resuello; Florea Lupu; Paul N Barlow; John D Lambris
Journal:  Immunobiology       Date:  2012-06-17       Impact factor: 3.144

8.  Cyclisation increases the stability of the sea anemone peptide APETx2 but decreases its activity at acid-sensing ion channel 3.

Authors:  Jonas E Jensen; Mehdi Mobli; Andreas Brust; Paul F Alewood; Glenn F King; Lachlan D Rash
Journal:  Mar Drugs       Date:  2012-07-16       Impact factor: 6.085

Review 9.  Automated solid-phase peptide synthesis to obtain therapeutic peptides.

Authors:  Veronika Mäde; Sylvia Els-Heindl; Annette G Beck-Sickinger
Journal:  Beilstein J Org Chem       Date:  2014-05-22       Impact factor: 2.883

Review 10.  Motif mediated protein-protein interactions as drug targets.

Authors:  Carles Corbi-Verge; Philip M Kim
Journal:  Cell Commun Signal       Date:  2016-03-02       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.